Market Trends Monte Rosa to focus on prostate cancer only for oncology asset MRT-2359By admin8996erT0allMarch 20, 2025 jamesbenet Monte Rosa Therapeutics (NASDAQ:GLUE) has decided to focus further development of MRT-2359, which targets the translation termination factor GSPT1,…
